

From: [Green, Jamie \(R7\)](#)
To: [Jepson, Scott](#); [kdhe.kda.rrt@ks.gov](#); [amber.grisamore@ks.gov](#); [Bowers, Ken \[KDA\]](#)
Cc: [Sleeter, Matthew R](#); [Gibbons, Samuel](#); [Moody, Jeffrey](#); [Weekley, Erin](#); [Barton, Kasey](#); [Beringer, Mike](#)
Subject: RE: EPA Concern with KS Wheat
Date: Monday, June 27, 2022 8:56:00 AM

Good morning

I appreciate everyone's quick attention to this.

Ex. 5 AWP / Ex. 7(A)

Ex. 5 AWP / Ex. 7(A)

We will connect internally here this morning to better understand what folks may have learned over the weekend on some of these questions and reach back.

Thanks again for your help.

Jamie

From: Jepson, Scott <Scott.Jepson@fda.hhs.gov>
Sent: Friday, June 24, 2022 4:57 PM
To: [kdhe.kda.rrt@ks.gov](#); [amber.grisamore@ks.gov](#); [Bowers, Ken \[KDA\]](#) <Ken.Bowers@ks.gov>
Cc: [Sleeter, Matthew R](#) <Matthew.Sleeter@fda.hhs.gov>; [Gibbons, Samuel](#) <Samuel.Gibbons@fda.hhs.gov>; [Moody, Jeffrey](#) <Jeffrey.Moody@fda.hhs.gov>; [Green, Jamie \(R7\)](#) <Green.Jamie@epa.gov>
Subject: EPA Concern with KS Wheat

Good Afternoon All,

Ex. 7(A)/ Ex. 5 AWP

Ex. 7(A)/ Ex. 5 AWP

Respectfully,

Scott A. Jepson

Investigator (Acting ERC)

U.S. Food and Drug Administration

Office of Regulatory Affairs

Kansas City District/HAFW2/Davenport Iowa Resident Post

Office # (563) 326-3323 Ext. 102

Cell # (210) 269-3339

Scott.Jepson@fda.hhs.gov

LOGO email



This e-mail message is intended for the exclusive use of the recipient(s) named above. It may contain information that is protected, privileged, or confidential, and it should not be disseminated, distributed, or copied to persons not authorized to receive such information. If you are not the intended recipient, any dissemination, distribution or copying is strictly prohibited. If you think you have received this e-mail in error, please e-mail the sender immediately. Non-official information and opinions are provided under the auspices of 21 CFR 10.85(k) - "A statement made or advice provided by an FDA employee constitutes an advisory opinion only if it is issued in writing under this section. A statement or advice given by an FDA employee orally, or given in writing but not under this section or Sec. 10.90, is an informal communication that represents the best judgment of that employee at that time but does not constitute an advisory opinion, does not necessarily

represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed.”